This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Huperzine A
Highly selective, reversible, BBB-penetrant AChE inhibitor extracted from Chinese club moss — 25-100× more potent than donepezil per mg…
Aliases (9)
Overview
What is Huperzine A?
Huperzine A is a sesquiterpene alkaloid extracted from Chinese club moss (Huperzia serrata). It is a highly selective, reversible, brain-penetrant acetylcholinesterase inhibitor used as a nootropic and as a treatment for Alzheimer's disease in China.
Key Benefits
Enhances memory and learning, improves attention and recall in healthy users and AD/MCI patients, supports neuroprotection against glutamate excitotoxicity, and is sometimes used to promote vivid or lucid dreaming when dosed pre-sleep.
Mechanism of Action
Reversibly inhibits acetylcholinesterase (AChE) at the synapse, increasing acetylcholine availability for cholinergic neurotransmission. Also acts as a non-competitive NMDA receptor antagonist at higher concentrations and shows mild antioxidant and beta-amyloid attenuating effects.
Pharmacokinetics
▸Brand options8 known
StatusOTC dietary supplement (US, DSHEA 1994); over-the-counter Rx-grade in China (registered drug for Alzheimer's, marketed as Selagine / Shuang Yi Ping); not FDA-approved as a drug in the US; not WADA-banned
Research Indications
Selectivity for AChE over BChE (butyrylcholinesterase) is ~1000:1
vs donepezil ~400:1, galantamine ~50:1, tacrine ~10:1, rivastigmine ~0.5:1 (rivastigmine actually prefers BChE). High AChE selectivity ma…
Peptide Interactions
✅ Mechanistically complementary — synthesis + clearance. Citicoline supplies choline for ACh synthesis; huperzine slows ACh breakdown. Stack produces larger,…
✅ Same logic as citicoline — synthesis substrate + clearance inhibition. Acute pre-task stack: alpha-GPC 300 mg + huperzine 50-100 mcg, 60-90 min pre-task. C…
✅ ALCAR provides the acetyl group; choline (from citicoline/alpha-GPC) provides the choline; huperzine slows breakdown. Three-way stack is mechanistically ti…
✅ Clean pre-task combo. Caffeine 100-200 mg + L-theanine 200 mg + huperzine 50-100 mcg, 60-90 min pre-task. Adenosine antagonism + α-wave + cholinergic = foc…
✅ Modafinil increases cortical activation → higher acetylcholine demand. Huperzine slows breakdown, citicoline supplies substrate. Anecdotally smooths modafi…
✅ Bromantane drives dopaminergic tone; huperzine drives cholinergic tone. Dopaminergic + cholinergic axes balance each other in cortical attention networks. …
✅ Membrane substrates for healthy cholinergic signaling. Stack-safe and synergistic.
❌ Cholinergic excess / crisis risk. Multiple AChE inhibitors stacked = additive AChE inhibition with no rate-limiting step. Severe nausea, bradycardia, hypot…
⚠️ Read labels — total daily huperzine across products is the relevant number. Don't stack a "huperzine stack" with standalone huperzine.
❌ Direct mechanistic antagonism — anticholinergic drugs block muscarinic receptors; huperzine raises ACh trying to activate the same receptors. Net effect: b…
❌ Prolonged paralysis risk. Succinylcholine is metabolized by BChE; huperzine is highly AChE-selective (1000:1) so this is theoretical, but other less-select…
⚠️ Additive bradycardia. Probably tolerable at moderate doses but watch HR.
Quality Indicators
Tested third-party COA
Reputable brands publish a Certificate of Analysis for identity, potency, and contaminant testing.
GMP-certified manufacturing
Look for cGMP / NSF / USP certifications on the label.
Proprietary blends
Avoid products that hide individual ingredient amounts inside a "proprietary blend."
No origin or sourcing info
Unbranded or no-COA capsules from anonymous sellers carry quality and adulteration risk.
What to Expect
- Onset60-90 min; peak 2-3 hr. Subtle. Many users feel nothing on the first dose, especially if choline-replete or first time.
- Onset60-90 min reliably. Peak 2-4 hr. Soft tail extends 8-10 hr.
Side Effects & Safety 9
Side Effects
- 1Vivid dreams (most common; cholinergic activation during REM)
- 2Mild GI upset — nausea, occasional loose stool, especially on empty stomach. Take with food.
- 3Mild headache — first dose, fades with subsequent dosing
- 4Mild sweating (cholinergic peripheral effect)
- 5Mild bradycardia (HR drop 5-10 bpm; transient; usually only noticed by users tracking with WHOOP/Oura/ring)
- 6Restlessness / mild agitation at higher doses (>200 mcg)
- 7Mild dizziness (especially with rapid escalation)
- 8Insomnia / sleep onset disruption if dosed past noon (long half-life tail into evening)
- 9Muscle fasciculations (eyelid twitch, occasional thigh/calf twitches; cholinergic NMJ activation; resolves on dose reduction)
When to Stop
- Cholinergic crisis at high doses or combined with other AChE inhibitors: severe nausea, vomiting, salivation, lacrimation, profuse sweating, bradycardia, hypotension, fasciculations, weakness. Treatment: atropine. Risk increases sharply when stacked with other AChE inhibitors (donepezil, galantamine, rivastigmine) or in users with BChE deficiency.
- Bronchoconstriction / asthma exacerbation — cholinergic stimulation of bronchial smooth muscle. Caution in asthmatics.
- Bradyarrhythmia / heart block — rare, dose-dependent; caution in users with sick sinus syndrome, AV block, or on beta-blockers/calcium channel blockers.
- Seizure threshold modulation — mixed evidence; cholinergic activation can be pro-convulsant in epilepsy patients but huperzine A is also being studied for *anti-epileptic* effects via NMDA antagonism. Use caution in seizure history.
- Cholinergic depression / mood flattening in chronic 200+ mcg/day users (case reports + anecdotal — same pattern as chronic alpha-GPC 1,200 mg)
- First 1-3 doses: GI tolerance, headache, sleep impact. Stop and reassess if severe nausea, profuse sweating, or HR drop >15 bpm.
- First 4 weeks of chronic use: mood/affect monitoring (cholinergic dysphoria can build slowly); HR check (resting bradycardia trend?); sleep quality (is the long tail tanking sleep?).
- 3 months chronic: sleep architecture review (REM dominance is fine acutely but sustained REM-shifted sleep can degrade NREM/SWS quality).
References
Xu SS et al. 1995, Acta Pharmacol Sin — Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease
keystone Chinese AD RCT, n=103, 400 mcg/day × 8 weeks.
View StudyZhang Z et al. 2002, Acta Pharmacol Sin — Clinical efficacy and safety of huperzine alpha in treatment of mild to moderate Alzheimer disease
n=202 Chinese AD RCT, 400 mcg/day × 12 weeks.
View StudyYang G et al. 2013, PLoS One — Huperzine A for Alzheimer's disease: a systematic review and meta-analysis
pooled meta-analysis of 20 Chinese RCTs, n=1823.
View StudyLi J et al. 2008, Cochrane Database Syst Rev — Huperzine A for Alzheimer's disease
Cochrane pooled analysis showing significant MMSE / ADL / global improvement.
View StudySun QQ et al. 1999, Acta Pharmacol Sin — Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students
closest evidence to "healthy young person memory benefit."
View StudyWang R et al. 2006, Neurosignals — Progress in studies of huperzine A: a natural cholinesterase inhibitor from Chinese herbal medicine
mechanism + neuroprotection review.
View StudyZangara A 2003, Pharmacol Biochem Behav — The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease
narrative review, foundational nootropic-community citation.
View StudyLallement G et al. 2002, Drug Chem Toxicol — Subchronic administration of huperzine A on cognitive performance and brain ChE activity in rats
military-context PK + subchronic dosing data.
View StudyGrunwald J et al. 1994, Life Sci — Huperzine A as a candidate for prophylaxis against organophosphate poisoning
early DARPA-era pharmacology paper.
View StudyLiu JS et al. 1986, Can J Chem — The structure of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity
original Chinese isolation and structure paper.
View StudyExamine.com — Huperzine A entry
community-facing dose/evidence/safety synthesis.
View StudyCognitive Vitality (ADDF) — Huperzine A research review
independent geroscience-focused review.
View StudyNootropics Depot — Huperzine A product page + CoA archive
third-party tested sourcing, batch CoAs.
View StudyPsychonautWiki — Huperzine A
community subjective effects synthesis, including lucid dream protocol.
View StudyReddit r/Nootropics — Huperzine A megathread
community anecdotes on PRN vs chronic dosing patterns and cycling.
View StudyTang XC, Han YF 1999, CNS Drug Rev — Pharmacological profile of huperzine A, a novel acetylcholinesterase inhibitor from Chinese herb
Chinese pharmacology consensus review.
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.